Abbott expects demand for its rapid COVID-19 tests to remain high through at least 2022, even if the current Omicron surge recedes.
During a “fireside chat” at the J.P. Morgan Healthcare Conference, Abbott CEO Robert Ford recalled that, early in the pandemic, Abbott correctly forecasted that demand for rapid tests would be...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?